Related Experiment Video
Updated: Jun 13, 2026
Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
Published on: October 25, 2017
ZL006 Treatment Reduces Inflammation, Oxidative Stress, and Brain Aβ1-42 Accumulation and Rescues the Loss of PSD95
Serena Ricci1, Maria Benuzzi1, Martina Fazzina1
1Department of Biological, Geological and Environmental Sciences (BIGEA), University of Bologna, 40126 Bologna, Italy.
Abstract:
Familial Alzheimer's disease (FAD) is a rare form of Alzheimer's. FAD is mainly caused by one or multiple mutations in the genes encoding for amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2), with the majority occurring in PSEN1. Despite extensive research in animal models and numerous promising treatment trials, there is still no curative treatment for FAD. Recently, ZL006 (Med Chem Express cat. Number HY-100456) was shown to reduce over-produced nitric oxide and oxidative stress in ischemic stroke and could protect neurons against Aβ1-42-induced neurotoxicity (in vitro study). With this in mind, we tested ZL006 at different doses (10 μM, 25 μM, 50 μM and 100 μM) in zebrafish embryo injected with ctrl-MO and psen1-MO, investigating the effects on pathological phenotype in vivo. We showed that ZL006 exposure suppresses inflammation, oxidative stress and accumulation of Aβ1-42 in psen1-MO. In conclusion, our study showed that ZL006 was able to ameliorate the pathological phenotype of psen1-morphant zebrafish embryos, supporting its potential as a candidate for further investigations in the context of FAD treatment.
Insights
ZL006, a potential therapeutic, reduced inflammation, oxidative stress, and amyloid-beta accumulation in a zebrafish model of Familial Alzheimer's disease (FAD). This compound shows promise for treating FAD by ameliorating pathological phenotypes.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Familial Alzheimer's disease (FAD) is a rare genetic form of Alzheimer's, primarily linked to mutations in APP, PSEN1, and PSEN2 genes.
- Current treatments for FAD are limited, despite extensive research and numerous clinical trials.
Purpose of the Study:
- To investigate the therapeutic potential of ZL006 in vivo using a zebrafish model of FAD.
- To evaluate ZL006's effects on pathological phenotypes associated with PSEN1 mutations.
Main Methods:
- Zebrafish embryos were injected with ctrl-morpholino (MO) or psen1-MO.
- ZL006 was administered at various doses (10–100 μM) to assess its impact on pathological phenotypes.
- Key markers including inflammation, oxidative stress, and amyloid-beta (Aβ1-42) accumulation were measured.
Main Results:
- ZL006 exposure significantly suppressed inflammation and oxidative stress in psen1-MO zebrafish embryos.
- The compound effectively reduced the accumulation of Aβ1-42 in the psen1-MO model.
- ZL006 demonstrated dose-dependent amelioration of pathological phenotypes.
Conclusions:
- ZL006 effectively ameliorated the pathological phenotype in psen1-morphant zebrafish embryos.
- The findings support ZL006 as a potential candidate for further investigation in Familial Alzheimer's disease treatment.
